


COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response

John F. McDyer, ... , Larry J. Dumont, Philip J. Norris

JCI Insight. 2023. <https://doi.org/10.1172/jci.insight.167890>.

Research In-Press Preview COVID-19 Immunology

Graphical abstract



Find the latest version:

<https://jci.me/167890/pdf>



COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response

John F. McDyer,^{1*} Mahzad Azimpouran,^{2*} Valerie L. Durkalski-Mauldin,³ Robert Clevenger,³ Sharon Yeatts,³ Xutao Deng,^{2,4} William Barsan,⁶ Robert Silbergleit,⁶ Nahed El Kassar,⁵ Iulia Popescu,¹ Dimiter Dimitrov,¹ Wei Li,¹ Emily J. Lyons,¹ Sophia C. Lieber,¹ Mars Stone,^{2,4} Frederick K. Korley,⁶ Clifton W. Callaway,¹ Larry J. Dumont,^{2,7} Philip J. Norris^{2,4}

¹University of Pittsburgh, Pittsburgh, Pennsylvania, USA

²Vitalant Research Institute, San Francisco, California, USA

³Medical University of South Carolina, Charleston, South Carolina, USA

⁴Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA

⁵National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA

⁶Department of Emergency Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA

⁷University of Colorado School of Medicine, Aurora, Colorado, USA

Corresponding author: Philip Norris, M.D., 360 Spear Street, Suite 200, San Francisco, CA 94105

(415) 923-5769

pnorris@vitalant.org

*These authors contributed equally to the work.

The authors have declared that no conflict of interest exists

Disclaimer: The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the NIH.

Abstract

Multiple randomized, controlled clinical trials have yielded discordant results regarding the efficacy of convalescent plasma in outpatients, with some showing an approximate two-fold reduction in risk and others showing no effect. We quantified binding and neutralizing antibody levels in 492 of the 511 participants from the C3PO trial of a single unit of COVID-19 convalescent plasma (CCP) vs. saline infusion. In a subset of 70 participants, peripheral blood mononuclear cells were obtained to define the evolution of B and T cell responses through day 30. Binding and neutralizing antibody responses were approximately two-fold higher one hour post-infusion in recipients of CCP compared to saline plus multivitamin, but levels achieved by the native immune system by day 15 were almost ten-fold higher than seen immediately after CCP administration. Infusion of CCP did not block generation of the host antibody response or skew B or T cell phenotype or maturation. Activated CD4⁺ and CD8⁺ T cells were associated with more severe disease outcome. These data show that CCP leads to a measurable boost in anti-SARS-CoV-2 antibodies, but that the boost is modest and may not be sufficient to alter disease course.

Introduction

Antibody based therapies have been shown to be effective treatment for COVID-19, particularly anti-SARS-CoV-2 monoclonal antibody (mAb) preparations which can be given in high doses (1). The weakness of mAb therapeutics is the relatively rapid mutation rate of SARS-CoV-2 (2), with multiple mAb therapeutics now rendered ineffective against circulating strains of the virus (3, 4). In theory, use of contemporary COVID-19 convalescent plasma (CCP) or hyperimmune globulin obtained from donors who recovered from COVID-19 in the prior six months would provide protection from severe disease and death and would target the contemporary circulating virus. Clinical trials using CCP plasma for COVID-19 have shown variable results. Most randomized clinical trials showed no benefit of CCP in hospitalized or critically ill patients (5–9), though some trials of hospitalized patients suggested benefit (10, 11). Two randomized trials showed a benefit from early receipt of CCP in outpatients, with approximately a 50% reduction in risk of hospitalization or disease progression in trials in Argentina and the CSSC-004 trial in the US (12, 13). A trial in the Netherlands was halted early after high vaccination levels in the population were achieved, but it showed a trend toward a reduction in hospitalizations after receipt of CCP with an effect size consistent with the Argentinian and CSSC-004 trials (14). In contrast, two randomized trials, the C3PO trial in the US and the CON-VERT trial in Spain showed no benefit of CCP in similar populations (15, 16). Preprint data from a meta-analysis suggest that in aggregate there is a 30% relative risk reduction for hospitalization after treatment of acute COVID-19 patients with CCP (17).

The C3PO trial enrolled participants who presented to the emergency department (ED) with acute COVID-19. The C3PO trial showed no significant benefit of CCP in preventing the primary

outcome, defined as a composite of hospital admission for any reason, seeking emergency or urgent care, or death without hospitalization within 15 days following randomization (15). Prior studies have suggested better outcomes associated with hyperimmune IVIG therapy in recipients who were seronegative compared to those who were seropositive prior to IVIG administration (18). The original publication of the C3PO trial results did not report baseline antibody levels prior to randomization (16). It is possible that CCP provides more benefit when administered to seronegative patients (19). In this current study of the C3PO trial, the levels of binding and neutralization antibodies were measured at four time points: baseline (pre-infusion), one hour post-infusion, day 15, and day 30. In addition, peripheral blood mononuclear cells were collected for a subset of 70 C3PO participants. Evolution of B and T cell responses was measured using flow cytometry to identify B cell maturation status, T cell activation, Treg levels, and SARS-CoV-2 specific T cell responses. We tested the hypotheses that baseline seropositivity or change in antibody levels with CCP administration were associated with clinical outcome and that CCP altered the endogenous antibody response during COVID-19.

Results

CCP antibody levels and responses to CCP administration

As previously reported, CCP was collected per FDA guidelines and was tested using a live-virus plaque reduction neutralization test (PRNT) at the Broad Institute.(15) An ID₅₀ of 1:250 was considered high titer by the FDA and eligible for transfusion as CCP. Screening of 1,598 donors eligible to donate CCP revealed that 66% met the threshold of an ID₅₀ ≥ 1:250 using the Broad Institute assay (Figure 1A). A total of 139 collections from 128 unique donors were used to create

doses of CCP infused to recipients in the C3PO trial, and the median titer of infused CCP units was 1:578 (IQR 1:445-1:1,692, Figure 1B).

Binding and neutralizing antibody levels were measured at baseline (BL; pre-infusion), post-infusion (PI; 1 h), day 15 and day 30. CCP recipients had almost a 3-fold increase in SARS-CoV-2 spike binding antibody levels from BL to PI, and the PI levels were significantly higher in the CCP compared to saline arm (Figure 2A). This difference was significant in participants who were seronegative at BL (Figure 2B), but not in those who were seropositive at BL (Figure 2C). There was considerable dilution of the CCP product after infusion, which can be seen by comparison of the titer in CCP with the paired titer PI in the recipients (Figure S1), particularly for those who were seronegative at BL (Figure S1A). By day 15 spike-specific antibody levels were significantly higher compared to BL/PI levels in both the CCP-treated group and saline group, with the increase in levels much larger than seen one hour after infusion of CCP. Increased spike-specific antibody levels were similar at day 15 versus day 30 in both groups, consistent with a peak in the endogenous spike antibody response. Despite only a modest correlation between spike binding antibody levels and neutralization titer (Spearman's $\rho=0.35$, Figure S2), similar results were obtained when neutralizing antibody titer was measured longitudinally in recipients. CCP recipients showed a 1.9-fold increase in ID₅₀ titer from BL to PI, and the level PI was significantly higher than in the saline arm (Figure 2D). As with binding antibodies, the increase in neutralization titer from BL to day 15 was much greater than that induced by infusion of CCP. A significant difference in neutralizing antibody titer between the saline and CCP groups at the PI time point was again seen in the participants who were seronegative but not those who were seropositive at BL (Figure 2E and F). Geometric mean titers are shown in Supplemental Table 2. The proportion

of participants PI who had a titer $\leq 1:100$ on an in-house RBD binding antibody ELISA was 77% in saline recipients (Figure 3A) vs. 21% in CCP recipients (Figure 3B). Together, these data show that CCP infusion had a significant impact on spike-specific antibody and neutralizing antibody activity, but that this increase was modest compared to levels generated by the host immune system by day 15 and did not significantly affect binding or neutralizing antibody responses in participants who were seropositive prior to CCP infusion.

Effect of baseline serostatus on disease outcome

The C3PO trial showed no significant benefit of CCP in preventing the primary outcome, disease progression defined as seeking ED or urgent care, hospitalization, or death within 15 days (15). Prior studies have suggested better outcomes associated with hyperimmune IVIG therapy in recipients who were seronegative compared to those who were seropositive prior to IVIG administration (18). We examined whether baseline serostatus was associated with modification of risk of disease progression in recipients of CCP. Using the RBD binding antibody assay, 41% of trial participants were seronegative upon presentation. Similarly, 49% of participants showed a neutralization titer $< 1:40$ at baseline. The unadjusted risk difference of disease progression for each assay had wide confidence intervals and did not differ depending on the participant's baseline serostatus (Table 2). These results show that within the C3PO trial population, baseline serostatus did not influence the treatment effect of CCP.

Cellular immunology study population

Seventy participants in the C3PO study were enrolled in a sub-study to measure the evolution of B and T cell responses and determine if they were influenced by receipt of CCP. Enrollment was

performed at the six medical centers with the highest projected enrollment and ability to ship whole blood samples overnight to San Francisco after collection. Participants included 38 males and 32 females, with a mean age of 52 (range 20-78). Among these individuals, 35 received CCP and 35 received normal saline plus multivitamins. Fourteen individuals were hospitalized, including one who was mechanically ventilated and required additional organ support. Details on the demographic and clinical characteristics of all participants are shown in Table 1.

Evolution of B and T cell responses

We first looked at the evolution of B cell populations at BL, Day15, and Day 30). B cells were gated as CD19+, with CD3, CD14, and CD56 used as dump parameters to eliminate T cells, monocytes, and NK cells. Plasmablasts were gated as CD38+ and CD27+ B cells.(20) CD38-/int cells were stained for IgD and CD27 expression. IgD- and CD27+ cells were defined as switched memory B cells and IgD+CD27+ as unswitched memory B cells. IgD+CD27- cells represented naïve B cells (Figure S3). Plasmablasts and unswitched memory B cell populations showed an increase by Day 15 compared to baseline (p -value:0.043 and 0.034, respectively). Switched memory B cells showed an increase at days 15 and 30 compared to baseline (p -value:0.040 & 0.010) (Figure 4). These results show that CCP does not impair the maturation of B cells post SARS-CoV-2 infection. In addition, the plasmablast response is not blunted in CCP compared to saline recipients.

CD4+ Treg cells were defined by Foxp3 vs CD25 expression. CD4+CXCR5+ circulating T follicular helper (cTfh) cells were plotted as ICOS+ vs. CD38+ to gate activated cTfh2. Activated CD4+ and CD8+ T cells were identified by CD137 vs. OX40 and CD69 expression, respectively

(Figure S4) (21). CD4⁺HLADR⁺CD38⁺ T-cells and activated circulatory follicular T helper cells (cTfh) showed an increase by Day30 and Day15 respectively (p -value:0.0324 & 0.0013) (Figure 5). Antigen specific T cells were identified by co-expression of CD137 and OX40 for CD4⁺ T cells and co-expression of CD137 and CD69 for CD8⁺ T cells after stimulation with a SARS-CoV-2 spike megapool of peptides (22) or PHA as a positive control (Figure S5). There was no change in the level of spike-specific T cells detected over 30 days for CD4⁺ or CD8⁺ T cells (Figure 6A). CD8⁺ T cells showed an increase in cells responding to PHA at days 15 and 30 compared to baseline (Figure 6B).

Correlation of cellular immune responses with receipt of CCP and with disease outcome

We next looked at differences in immune profiles between CCP and saline recipients. There was no significant association between any of the cellular phenotypes measured and receipt of CCP (Figure S6). We also looked at cellular phenotypes based on the primary outcome (death, hospitalization, or ED/UC visit within 15 days post-randomization), disease progression on the COVID-19 outpatient ordinal scale within 15 days (symptom worsening), and 8-point illness severity scale ≥ 3 . The 8-point scale was adapted from a February 2020 WHO COVID-19 Ordinal Scale for Clinical Improvement, where a score of 1 is asymptomatic, ≥ 3 is hospitalized, and 8 is death (23). There was a significant correlation between worst COVID-19 outcome on the 8-point scale and activated cTfh cells (p -value: 0.005) and CD38 and HLA-DR up-regulation on CD4⁺ T cells (p -value: 0.008) and CD8⁺T-cells (p -value: 0.002) (Figure 7). These results demonstrate that CCP does not decrease the pro-inflammatory environment of acute COVID-19, but that increased T cell activation is associated with more severe symptoms in an outpatient population.

Antibody levels in C3PO trial recipients were not correlated with B or T cell phenotypes

We explored the correlation between antibody levels and cellular immune parameters using Spearman correlation. We first examined whether antibody levels correlated with cellular immune responses at each time point (baseline, Day 15, and Day 30) as well as whether cellular responses correlated with the change in antibody response from baseline to day 15 or day 30. None of the cellular phenotypes showed a significant correlation with concurrent antibody levels or change in antibody levels.

Discussion

We found that infusion of one unit of high-titer CCP significantly increased anti-SARS-CoV2 RBD-specific IgG, anti-SARS-CoV2 spike IgG and neutralizing antibody levels in recipients. Despite these increases in antibody levels, we did not observe a significant difference in hospitalization within 28 days, the primary outcome of the C3PO trial. Moreover, levels achieved post-infusion of CCP were significantly lower compared to endogenously generated antibody levels at days 15 or 30, suggesting that despite ‘high-titer’ CCP, the impact on circulating antibody levels was modest. Our findings indicate that CCP administration did not negatively impact the host antibody response to SARS-CoV2, as the day 15 and 30 levels did not differ between the CCP and saline arms. Additionally, detailed examination of cellular immune responses showed that B and T cell maturation were not affected by CCP administration. Finally, we found that that CD4+ and CD8+ T cell activation was associated with more severe disease outcome.

We observed that those with lower anti-S antibody titers at baseline had the most significant boost in RBD-specific antibody levels; thus those with higher titer baseline levels of RBD-specific antibody appear to have derived the least immune impact from CCP administration. Nonetheless,

when stratified for seronegative individuals who received CCP versus saline, these individuals still did not derive significant impact on the primary outcome. Thus, the CCP-induced increase in antibodies was insufficient to alter the clinical course of COVID-19, including in seronegative patients. Retrospective studies suggest that CCP improves survival in hematological malignancies (24, 25), and a randomized, controlled trial found improved survival in cancer patients who received CCP (26).

It has been shown that anti-SARS-CoV-2 mAb therapy is an effective therapy in preventing severe COVID-19 or death, at least in virus variants that have not yet escaped the antibody sequence. The level of anti-SARS-CoV-2 antibody delivered with mAb therapy is higher than that contained in even high-titer CCP. While it is difficult to compare antibody values across assays, the FDA lists high-titer CCP as $\geq 1,280$ AU/ml for the Abbott ARCHITECT assay and >55 RU/ml for the EUROIMMUN assay used in our study. Anti-S IgG levels within 48 hours after infusion of 1,200 mg REGN-COV mAb cocktail ranged from $>80,000$ to 332,000 arbitrary units (AU)/ml using the Abbott ARCHITECT assay, orders of magnitude higher than the FDA cutoff for high-titer CCP (27). The median level observed after CCP administration using the ERUOIMMUN assay was 0.78 RU/ml, almost two orders of magnitude below the FDA threshold for high-titer CCP. Consistent with mAbs delivering a much higher dose of antibody, SARS-CoV-2-specific antibody levels declined 60% by day 12 after mAb infusion (27). while they increased substantially by day 15 in our study of CCP recipients.

Four recent randomized, controlled trials of CCP in outpatients were evenly split between those showing efficacy (12, 13) and those showing no effect (15, 16), with a fifth showing potential

efficacy that did not reach statistical significance (14). There were some differences in trial design, such as the positive CSSC-004 and Dutch trials using pre-COVID-19 plasma rather than normal saline as a placebo (13, 14), which could favor CCP if the plasma itself were associated with adverse outcomes, or C3PO enrolling subjects presenting to the ED (15), which may bias toward participants too far advanced in their disease course to benefit from CCP. However, the Argentinian CCP trial used normal saline as the placebo and still showed the same positive effect size as the CSSC-004 trial (12), implying that using plasma in the control arm was not responsible for the positive effect seen in that trial. Conversely, the CON-VERT study in Spain was performed using community participants rather than those presenting to the ED and showed no effect of CCP (16), implying that recruiting subjects in the ED alone does not entirely explain why the C3PO trial did not show a treatment effect for CCP. The titer of CCP administered across these four trials was marginally lower in the positive efficacy trials compared to the negative trials, though the same neutralization assay was not used to test samples from the different trials (17), arguing that the dose of antibody was not the sole determinate of outcome in the CCP trials. Recent data suggest that N-specific Fc-mediated antibody maybe an important effector pathway for CCP (28), and in mouse models CCP with low neutralization activity can still provide some protection from SARS-CoV-2 through Fc-mediated functions such as antibody dependent cellular cytotoxicity (29).

Our data showed that activated CD4⁺ and CD8⁺ T cells were associated with more severe disease outcome on an 8-point scale, but that receipt of CCP did not affect B or T cell population phenotypes. We hypothesized that receipt of CCP might have blunted the host anti-S antibody response, in part due to historical studies such as the use of anti-D antibody to block Rh

immunization (30). Two studies of monoclonal antibody therapy suggest modest suppression of host anti-S antibody responses, either through monitoring of antibodies targeting regions of spike not targeted by the monoclonal antibody (31) or via measuring anti-S IgM in patients vs. controls treated with monoclonal antibody therapy (32). In contrast, a study of CCP showed no difference in anti-spike antibody levels within days after therapy between those who did or did not receive CCP (14), consistent with our findings. It is tempting to speculate that the dose of anti-S antibody administered in CCP is not sufficient to blunt host B cell responses.

While the current study draws on the strength of examining samples from a controlled, randomized trial, there are several limitations. Study of early evolution of antibody and cellular immune responses inside the two-week window were not possible given the timing of sample collection. Binding and neutralizing capability of antibody responses were quantified, but other antibody driven functions such as antibody dependent cellular cytotoxicity were not studied. Examination of cellular immune responses was performed by flow cytometry, and differences in minor populations of immune cells or other functional responses could exist that would be detected by in-depth examination with techniques such as single-cell RNA-Seq.

In summary, we found that infusion of CCP raised anti-SARS-CoV-2 antibody levels modestly immediately post-infusion, but to a much lower level than that achieved by the host immune response at day 15. Receipt of CCP did not blunt the native immune response at the level of antibody titer or T or B cell maturation state. Participants who had lower baseline levels of anti-SARS-CoV-2 antibodies experienced a greater increase in antibody titer after CCP infusion, but the clinical outcome was not improved in this subset of participants compared to the overall trial

population. Comparing the antibody levels achieved in C3PO to similar randomized trials of CCP in outpatients, we cannot identify a difference that would account for discrepant trial results. One possible interpretation of the multiple clinical trials would be that the overall dose of anti-SARS-CoV-2 antibody contained in a unit of CCP is low compared to that achieved using monoclonal antibody preparations or generated by the immune system after natural infection. It is possible that higher titer CCP may produce more consistent positive results than currently defined high-titer CCP. It has been reported that plasma collected from CCP donors who had received SARS-CoV-2 vaccination possess higher neutralizing antibody activity than those who remained unvaccinated (33), which will allow exploration of next-generation CCP for eligible patients.

Methods

Study population

The COVID-19 Convalescent Plasma in Outpatients (C3PO) clinical trial was a phase 3, multicenter, randomized, single-blind, placebo-controlled trial that enrolled ED patients presenting with mild COVID-19. Participants received either one unit of high titer CCP or 250 ml of saline with multivitamins, hereafter referred to as “saline”. Eligible participants were ≥ 50 -years-old or had one or more risk factors for disease progression, presented to the ED ≤ 7 days after symptom onset, and were deemed by the clinical team stable for outpatient management without supplemental oxygen. Exclusion criteria included patients ≤ 18 -years-old, prisoners or wards of the state, inability to complete follow-up assessments, history of adverse reactions from transfusion, or inability to receive 250 ml of fluid. Patients who had received blood products within the past 120 days or another investigational treatment for COVID-19, including anti-SARS-CoV-2 mAbs or vaccination, were excluded. Enrollment ran from August 2020 through February 2021 at 48

EDs in 21 states. Participants with a baseline and ≥ 1 post-baseline antibody assay result were included in the current analysis.

COVID-19 convalescent plasma

CCP was collected from donors according to the FDA guidance for donor eligibility. CCP units were qualified primarily with a live-virus, plaque reduction test (PRNT) performed by the Broad Institute. Units with a 50% inhibitory dilution (ID_{50}) of $\geq 1:250$ eligible to be transfused.

Sample collection and processing

Blood samples were obtained from consenting participants prior to study drug infusion (baseline, BL), one hour post-infusion (PI), and on days 15 (D15) and 30 (D30) following randomization. Blood samples were processed into serum and plasma, aliquoted, and stored locally at -70°C . Study samples were shipped to a central biorepository at the University of Pittsburgh then to the analytic laboratories.

Cellular immunology sub-study participants and sample collection

A subset of 70 C3PO participants presenting to six high-enrolling centers in the C3PO study (Baystate Health, Cooper, Maine Medical, Michigan Medicine, Spectrum Health, and UCLA) was included for study of cellular immune responses. Samples were collected pre-transfusion and at days 15 and 30. Blood was collected in two 10 ml EDTA tubes and shipped overnight at ambient temperature to Vitalant Research Institute in San Francisco. Ficoll-Paque (Lymphoprep, Stemcell Technologies) was used for the isolation of peripheral blood mononuclear cells (PBMCs). PBMCs

were cryopreserved in FBS (heat-inactivated, Hyclone Laboratories) with 10% dimethyl sulfoxide (DMSO, Sigma) and stored in liquid nitrogen in 5×10^6 cell aliquots.

Binding antibody detection

Anti-SARS-CoV-2 RBD antibodies were detected using an ELISA customized at the University of Pittsburgh. 96-well plates were coated with 50 μ l of recombinant RBD (20 μ g/ml) overnight at 4°C then blocked with 100 μ l of skim milk for 1 hour at 4°C then washed using 150 μ l of PBS. Plasma samples were serially diluted (1:100, 1:400, 1:1600, etc.) in skim milk, and 50 μ l was added to the plate and incubated for 1 hour at 37°C. Plates were washed and 50 μ l of goat anti-human IgG HRP-labeled secondary antibody (Southern Biotech) (diluted to 1:3000 with skim milk) was added and incubated for 1 hour at 25°C. Plates were washed and 50 μ l of TMB substrate was added and incubated for 7 minutes before adding 50 μ l of stop solution (0.16M H₂SO₄). Plates were read at 450 nm to obtain optical density (OD) values. An OD value threshold of 0.3 was set for positivity, which was twice the level seen in blank wells.

Total antibodies against SARS-CoV-2 S1 were measured using a commercially available ELISA (EUROIMMUN) according to the manufacturer's directions. Assay results were reported as a ratio of OD of the clinical sample to OD of a calibrator. An OD ratio <0.8 was considered negative, ≤ 0.8 to <1.1 borderline, and ≥ 1.1 positive.

Neutralizing antibody detection

Neutralizing antibody levels were measured by the Broad Institute using a live-virus SARS-CoV-2 PRNT as previously described.(34) Neutralizing antibody serum samples were tested at a 1:40

dilution then serially diluted 4-fold up to four dilution spots then mixed with live SARS-CoV-2 (D614) for one hour. The mixture was added to Vero E6-TMPRSS2 cells for 48 hours, then infected cells were detected with anti-SARS-CoV2 nucleoprotein mouse primary antibody (Sino Biological) and a secondary Alexa488-conjugated goat anti-mouse antibody (Jackson ImmunoResearch Labs).

Flow Cytometry Analysis

Cells were thawed in 15 ml prewarmed RPMI (Gibco), then 10^6 cells were resuspended in 96-well V-bottom polystyrene plates and stained with Zombie Aqua/Nir (BioLegend) and washed prior to surface staining with a surface antibody cocktail for 30 min at 4°C in the dark. Following surface staining, cells were washed twice with PBS plus 2% fetal bovine serum. For intracellular staining cells were resuspended with 100 μ l BD Cytotfix/Cytoperm™ for 15 min at 4°C in the dark, then washed twice with BD Perm/Wash™ buffer and resuspended in 50 μ l of BD Perm/Wash™ buffer containing Foxp3-PE and incubated at 4°C for 30 min in the dark. Cells were washed twice with 250 μ L BD Perm/Wash™ buffer and resuspended in PBS prior to flow cytometric analysis. A list of antibodies for these panels can be found in Table S1. Samples were run on a Cytex Aurora 5-Laser cytometer. Samples were tested blinded in batches of 8-16, with 250,000 cells acquired per sample. A replicate PBMC sample from the same healthy donor was included in each batch. Data analysis was performed with SpectroFlo software.

Measuring SARS-CoV-2-specific T cells

Peptides spanning SARS-CoV-2 spike (S) glycoprotein, 13- or 17-mers overlapping by 10 amino acids (n=181), were obtained from BEI Resources (Peptide array NR-52402), reconstituted with

25 μ l DMSO, pooled and re-lyophilized.(35) The lyophilized megapool was resuspended in 500 μ l DMSO and 1.5 ml H₂O. Cells were incubated with of SARS-CoV-2 peptide pool (1 μ g/ml) or PHA-L (1.25 mg/ml, Invitrogen) for 24 hours at 37°C, 5% CO₂. The next day cells were stained with Zombie Aqua (BioLegend) and for surface markers.

Statistical Analysis

Antibody data were analyzed using SAS V9.4 or higher (SAS Institute). Assay results were positively skewed, so were transformed to a natural log scale for analyses. The effect of treatment on antibody levels over time was evaluated using a generalized linear model adjusting for multiple comparisons. The MIXED procedure in the SAS system was used to fit the model and included an interaction term for treatment group and visit day. Unadjusted risk differences with 95% confidence intervals are reported for the assessment of CCP's effect on disease progression within serostatus subgroups for both the binding and neutralizing antibody assays.

Cellular immune data were analyzed using GraphPad Prism v.9.1.2. A mixed effect analysis was performed with a Šidák's multiple comparison test to compare across time points, and p values <0.05 were considered statistically significant. We used a linear mixed-effect model to evaluate the association between outcome and cellular immune phenotypes (R LME4 package). Specifically, we used correlated random intercept and slope to generate the model, where subjects are random effect variables, visit and outcome are fixed effect variables, and B cell and T cell phenotype are response variables. Samples with cell viability <90% were excluded from the analysis.

Study approval

The Food and Drug Administration (FDA) approved an Investigational New Drug application for the trial. A central institutional review board (Advarra) reviewed and approved the trial protocol for all participating sites. An independent medical safety monitor reviewed and adjudicated all serious adverse events, and the National Heart, Lung, and Blood Institute appointed the independent data and safety monitoring board. All participants were enrolled under written informed consent.

Author Contributions

JFM, NEK, FKK, CWW, LJD, and PJN conceived of the study. WB, RS, and LJD contributed clinical samples. MA, MS, IP, DD, WL, E JL, and SCL performed experiments. VLD, RC, SY, and XD performed data analysis. PJN, VLD, and JFD wrote the manuscript.

Funding

This study was supported by awards (1OT2HL156812-01, U24NS100659, and U24NS100655) from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health and by a contract (75A50120C00094) with the Biomedical Advanced Research and Development Authority (BARDA) through the Department of Health and Human Services and the Operation Warp Speed interagency program. Support included funding and material support in the form of plasma and testing supplies. The research was, in part, funded by the National Institutes of Health (NIH) Agreement 1OT2HL156812 through the CONNECTS program.

Acknowledgments

The graphical abstract was created with BioRender. We would like to thank Niklas Koehne for assistance with the immune cell phenotyping experiments.

Disclosures of conflicts of interest

None of the authors declare any conflicts of interest.

References

1. Focosi D, et al. Monoclonal antibody therapies against SARS-CoV-2. *Lancet Infect Dis* 2022;S1473-3099(22)00311–5.
2. Sharif N, et al. Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019-2022. *PLoS One* 2022;17(8):e0271074.
3. VanBlargan LA, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. *Nat Med* 2022;28(3):490–495.
4. Cao Y, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* 2022;602(7898):657–663.
5. Agarwal A, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). *BMJ* 2020;371:m3939.
6. Li L, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA* [published online ahead of print: June 3, 2020]; doi:10.1001/jama.2020.10044


7. Abani O, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. *The Lancet* 2021;397(10289):2049–2059.
8. Avendaño-Solá C, et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. *Journal of Clinical Investigation* 2021;131(20):e152740.
9. Bégin P, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. *Nat Med* [published online ahead of print: September 9, 2021]; doi:10.1038/s41591-021-01488-2
10. Bar KJ, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. *J Clin Invest* 2021;131(24):e155114.
11. O'Donnell MR, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. *J Clin Invest* 2021;131(13):150646.
12. Libster R, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med* 2021;384(7):610–618.
13. Sullivan DJ, et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. *N Engl J Med* 2022;NEJMoa2119657.
14. Gharbharan A, et al. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial. *Clinical Microbiology and Infection* 2022;S1198743X22004219.

15. Korley FK, et al. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. *N Engl J Med* [published online ahead of print: August 18, 2021]; doi:10.1056/NEJMoa2103784
16. Alemany A, et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. *The Lancet Respiratory Medicine* 2022;10(3):278–288.
17. Levine AC, et al. COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized Trials. *medRxiv* 2022;2022.12.16.22283585.
18. Polizzotto MN, et al. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. *The Lancet* 2022;399(10324):530–540.
19. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. *Lancet* 2021;397(10289):2049–2059.
20. Stathopoulos P, et al. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. *JCI Insight* 2017;2(17):94263.
21. Mathew D, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science* 2020;eabc8511.

22. Grifoni A, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* [published online ahead of print: May 20, 2020]; doi:10.1016/j.cell.2020.05.015
23. World Health Organization (WHO) COVID-19 Trial Design Draft Master Protocol https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf. cited
24. Thompson MA, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA Oncol* [published online ahead of print: June 17, 2021]; doi:10.1001/jamaoncol.2021.1799
25. Hueso T, et al. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. *Leukemia* 2022;36(4):1025–1034.
26. Denkinger CM, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. *Nat Cancer* [published online ahead of print: December 29, 2022]; doi:10.1038/s43018-022-00503-w
27. Sasaki H, et al. High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV. *Infection* [published online ahead of print: February 18, 2022]; doi:10.1007/s15010-022-01779-x

28. Herman JD, et al. Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy. *Cell Reports Medicine* 2022;3(11):100811.
29. Ullah I, et al. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. *Cell Reports Medicine* 2023;4(1):100893.
30. Bowman JM. The Prevention of Rh Immunization. *Transfusion Medicine Reviews* 1988;2(3):129–150.
31. Zhang L, et al. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together. *Front. Immunol.* 2021;12:790469.
32. Kim PS, et al. Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response. *Clinical Immunology* 2022;236:108959.
33. Sullivan DJ, et al. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. *Nat Commun* 2022;13(1):6478.
34. Di Germanio C, et al. SARS-CoV -2 antibody persistence in COVID -19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance. *Transfusion* 2021;61(9):2677–2687.
35. Carrasco Pro S, et al. Automatic Generation of Validated Specific Epitope Sets. *J Immunol Res* 2015;2015:763461.

(A)



(B)





Figure 1. Convalescent plasma neutralization titer distribution.

(A) Screening of ID₅₀ neutralization titers was performed at the Broad Institute for 1,598 donors who met clinical criteria for convalescent plasma donation. (B) The distribution of neutralization titers is shown for the 139 convalescent plasma units used to make doses that were transfused in the C3PO trial. Red bars on each graph denote units that met the FDA guideline threshold of ID₅₀ ≥1:250 for designation of high-titer convalescent plasma and blue bars denote units that fell below the threshold.

Binding Antibody



Neutralization titer





Figure 2. Evolution of antibody responses in study participants.

(A) Binding antibody responses were measured using an ELISA from EUROIMMUN, and the natural log of the ratio of the sample OD to a calibrator OD is shown for the saline (black line) vs. CCP (orange line) recipients across the four sample time points. Individual participants' data are shown in gray lines with the average for the saline (black) and CCP (orange) recipients plotted for subjects who were (B) seronegative for binding antibodies at BL or (C) seropositive for binding antibodies at BL. (D) Neutralizing antibody activity was measured using the BROAD Institute assay and reported as the 50% inhibitory dose (ID_{50}). Results separated by (E) participants who were seronegative or (F) seropositive at baseline for neutralizing antibody activity (titer threshold of 1:40). Error bars represent 95% confidence limits for the mean, **** $p < 0.0001$ for saline vs. CCP groups at each time point.

(A)



(B)




Figure 3. Evolution of RBD binding antibody titer in recipients of saline vs. CCP.

RBD binding antibody titers were calculated using endpoint dilutions, with positive values defined as titer $\geq 1:400$. Sankey diagrams illustrate the proportion of subjects with a given antibody titer at each time point, and their flow to the next titer is indicated by shaded lines between the bars representing each time point for (A) Saline and (B) CCP recipients.




Figure 4. Evolution of B cell responses.

CCP and saline populations were combined to measure B cell phenotypes across three time points in all subjects with PBMC samples: Baseline, Day 15 and Day 30 for (A) B cells, (B) plasmablasts, (C) switched memory B cells, (D) naïve B-cells, (E) CD27-IgD- B cells and (F) unswitched memory B cells. The replicate control group on each graph represents a replicate aliquot of a single healthy control run with each batch on the flow cytometer. Time points were compared with a mixed-effects model with a Sidak's multiple comparison test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$




Figure 5. T cell phenotype evolution.

CCP and saline populations were combined to measure T cell phenotypes across three time points in all subjects with PBMC samples : Baseline, Day 15 and Day 30 for (A) CD4+ T cells, (B) CD4+HLA-DR+CD38+ T cells, (C) Treg cells, (D) CD8+ T cells, (E) CD8+HLA-DR+CD38+ T cells, (F) cTfh cells, and (G) activated cTfh cells. The replicate control group on each graph represents a replicate aliquot of a single healthy control run with each batch on the flow cytometer. Time points were compared with a mixed-effects model with a Sidak's multiple comparison test. * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$




Figure 6. Frequency of SARS-CoV-2-specific T cells.

CCP and saline populations were combined to measure T cell phenotypes across three time points in all subjects with PBMC samples : Baseline, Day 15 and Day 30 for (A) CD4+ and (B) CD8+ T cells. Spike-specific T cells were defined as the percentage of positive cells in the peptide-stimulated minus unstimulated populations. Time points were compared with a mixed-effects model with a Šidák's multiple comparison test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Figure 7. Correlation between disease severity and activated T cell populations.

All 22 cellular immune phenotypes were analyzed for association with disease outcome, with the 8-point severity scale categorized as < 3 or ≥ 3 . Subjects who reported ≥ 3 symptoms on an 8-point severity scale are represented in red, and those with < 3 symptoms in blue.

Populations that showed increased levels in patients with score ≥ 3 included (A) CD4+CD38+HLA-DR+ T cells, (B) CD8+CD38+HLA-DR+ T cells, and (C) activated cTfh cells, which were CD3+CD4+CD45RA-CXCR5+CD38+ICOS+ cells. Comparisons were made using a linear mixed-effect model to determine significant associations. Error bars represent standard error of the mean.

Table 1: Baseline Characteristics of Study Population

	Overall n=492	Substudy n=70
Age – median (interquartile range)	54 (41, 61)	55 (40, 64)
Female - no. (%)	259 (52.6)	32 (45.7)
Race - no. (%)		
Asian	17 (3.5)	3 (4.3)
Black	98 (19.9)	7 (10.0)
Other	50 (10.2)	5 (7.1)
White	327 (66.5)	55 (78.6)
Ethnicity - no. (%)		
Hispanic or Latino	152 (30.9)	28 (40.0)
Not Hispanic or Latino	334 (67.9)	40 (57.1)
Unknown	6 (1.2)	2 (2.9)
Eligibility Risk Factors - no. (%)		
Age >=50	298 (60.6)	45 (64.3)
BMI greater than or equal to 30	293 (59.6)	43 (61.4)
Hypertension	207 (42.1)	37 (52.9)
Tobacco use (current or former)	143 (29.1)	22 (31.4)
Diabetes mellitus	137 (27.9)	25 (35.7)
COPD or asthma	120 (24.4)	14 (20.0)
Coronary artery disease	49 (10.0)	7 (10.0)
Immunosuppression	50 (10.2)	6 (8.6)
Chronic lung disease	31 (6.3)	4 (5.7)
Chronic kidney disease	28 (5.7)	5 (7.1)
Congestive heart failure	20 (4.1)	2 (2.9)
Currently Pregnant	5 (1.0)	1 (1.4)
Organ transplant	5 (1.0)	1 (1.4)
Active cancer	3 (0.6)	0 (0.0)
Sickle cell	1 (0.2)	0 (0.0)
Number of Eligibility Risk Factors - no. (%)		
1	114 (23.2)	17 (24.3)
2	125 (25.4)	10 (14.3)
3 or more	253 (51.4)	43 (61.4)
Other Comorbidities - no. (%)		
Alcohol abuse (current or former)	34 (6.9)	4 (5.7)

	Overall n=492	Substudy n=70
Drug abuse (current or former)	33 (6.7)	1 (1.4)
Thromboembolic disorder	24 (4.9)	1 (1.4)
Liver disease	16 (3.3)	5 (7.1)
Other hematologic disorders	16 (3.3)	2 (2.9)
Seronegative on the Broad Assay (n=479 -no (%))	238 (49.7)	33 (47.1)
Seronegative on the RBD Assay (n=488) -no (%)	200 (41.0)	31 (44.3)
Symptom duration prior to randomization (days) – median (interquartile range)	4 (2, 5)	3 (2, 5)
Time from randomization to infusion start (min) - median (interquartile range)	81 (63, 110)	76 (61, 114.5)

Table 2. C3PO Primary Efficacy Outcome Overall, by Assay, and by Baseline Serostatus

Primary Efficacy Outcome*	CCP	Saline	Risk Difference (95% CI)
Overall Population[¶] (N=492)			
Patients with an event – n/N (%)	73/246 (29.7)	78/246 (31.7)	2.0% (-6.1, 10.2)
Broad Assay (N=479)			
Seronegative Patients with an event – n/N (%)	35/122 (28.9)	29/116 (25.0)	-3.7% (-14.9, 7.6)
Seropositive Patients with an event – n/N (%)	35/116 (30.2)	48/125 (38.4)	8.2% (-3.7, 20.2)
RBD Assay (N=488)			
Seronegative Patients with an event – n/N (%)	36/113 (31.9)	30/86 (34.9)	3.0% (-10.2, 16.3)
Seropositive Patients with an event – n/N (%)	36/131 (27.5)	47/158 (29.8)	2.3% (-8.2, 12.7)

*The C3PO primary efficacy outcome of disease progression was defined as an emergency department (ED) or urgent care (UC) visit, hospital admission or death without a hospital admission within 15-days from randomization.

[¶]The overall population is defined as randomized C3PO patients who had a baseline assay result and at least 1 post-baseline assay result.